CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · Real-Time Price · USD
0.5800
-0.0558 (-8.78%)
Apr 1, 2025, 4:00 PM EDT - Market closed
CytomX Therapeutics Revenue
In the year 2024, CytomX Therapeutics had annual revenue of $138.10M with 36.45% growth. CytomX Therapeutics had revenue of $38.09M in the quarter ending December 31, 2024, with 43.17% growth.
Revenue (ttm)
$138.10M
Revenue Growth
+36.45%
P/S Ratio
0.39
Revenue / Employee
$1,141,347
Employees
121
Market Cap
46.46M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 138.10M | 36.89M | 36.45% |
Dec 31, 2023 | 101.21M | 48.05M | 90.38% |
Dec 31, 2022 | 53.16M | 15.85M | 42.48% |
Dec 31, 2021 | 37.31M | -31.12M | -45.47% |
Dec 31, 2020 | 68.43M | 41.53M | 154.36% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
CTMX News
- 25 days ago - CytomX Therapeutics, Inc. (CTMX) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 25 days ago - CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 27 days ago - CytomX Therapeutics to Present at the Barclays 27th Annual Global Healthcare Conference - GlobeNewsWire
- 4 weeks ago - CytomX Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 - GlobeNewsWire
- 3 months ago - CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update - GlobeNewsWire
- 4 months ago - CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference - GlobeNewsWire
- 5 months ago - CytomX Therapeutics, Inc. (CTMX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 5 months ago - CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire